Compare AbbVie Inc (ABBV) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Peloton Interactive Inc — how do they compare? AbbVie Inc trades at $253.51 (market cap $449.91B), while Peloton Interactive Inc trades at $5.71 (market cap $2.52B). The key difference: AbbVie Inc is far larger — about 178.5× Peloton Interactive Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| ABBV | PTON | |
|---|---|---|
Market Cap | $449.91B | $2.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $9.00 |
52-Week Low | $184.85 | $3.71 |
Enterprise Value | $513.38B | $3.12B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Peloton (PTON) trades at $5.82, up 1.22% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals, with operating cash flow turning positive to $333 million in 2025 and net losses narrowing significantly. Recent news highlights a potential turnaround, including inclusion in the S&P SmallCap 600 index and the appointment of a new CFO.
The outlook is cautiously optimistic as Peloton aims for profitability, but risks remain from high debt and revenue declines. Analyst consensus is a Buy with a $7.50 price target, suggesting 29% upside, though execution on growth initiatives is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
